• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核受体调节剂的化学筛选。

Chemical Screening of Nuclear Receptor Modulators.

机构信息

Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan.

出版信息

Int J Mol Sci. 2020 Jul 31;21(15):5512. doi: 10.3390/ijms21155512.

DOI:10.3390/ijms21155512
PMID:32752136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7432305/
Abstract

Nuclear receptors are ligand-inducible transcriptional factors that control multiple biological phenomena, including proliferation, differentiation, reproduction, metabolism, and the maintenance of homeostasis. Members of the nuclear receptor superfamily have marked structural and functional similarities, and their domain functionalities and regulatory mechanisms have been well studied. Various modulators of nuclear receptors, including agonists and antagonists, have been developed as tools for elucidating nuclear receptor functions and also as drug candidates or lead compounds. Many assay systems are currently available to evaluate the modulation of nuclear receptor functions, and are useful as screening tools in the discovery and development of new modulators. In this review, we cover the chemical screening methods for nuclear receptor modulators, focusing on assay methods and chemical libraries for screening. We include some recent examples of the discovery of nuclear receptor modulators.

摘要

核受体是配体诱导的转录因子,可控制多种生物学现象,包括增殖、分化、繁殖、代谢和维持内稳态。核受体超家族的成员具有明显的结构和功能相似性,其结构域功能和调节机制已得到充分研究。各种核受体调节剂,包括激动剂和拮抗剂,已被开发为阐明核受体功能的工具,也被开发为候选药物或先导化合物。目前有许多用于评估核受体功能调节的测定系统,可作为新调节剂的发现和开发的筛选工具。在这篇综述中,我们涵盖了核受体调节剂的化学筛选方法,重点介绍了用于筛选的测定方法和化学文库。我们还包括一些核受体调节剂发现的最新实例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd6a/7432305/e63bbe1d0081/ijms-21-05512-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd6a/7432305/3007a0c5369b/ijms-21-05512-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd6a/7432305/e63bbe1d0081/ijms-21-05512-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd6a/7432305/3007a0c5369b/ijms-21-05512-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd6a/7432305/e63bbe1d0081/ijms-21-05512-g002.jpg

相似文献

1
Chemical Screening of Nuclear Receptor Modulators.核受体调节剂的化学筛选。
Int J Mol Sci. 2020 Jul 31;21(15):5512. doi: 10.3390/ijms21155512.
2
Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.通过三维形状相似性搜索和基于结构的虚拟筛选发现新型非甾体类法尼醇X受体调节剂。
Chem Biol Drug Des. 2015 Apr;85(4):481-7. doi: 10.1111/cbdd.12432. Epub 2014 Oct 10.
3
Importance of the pharmacological profile of the bound ligand in enrichment on nuclear receptors: toward the use of experimentally validated decoy ligands.结合配体的药理学特征在核受体富集中的重要性:走向使用经过实验验证的诱饵配体。
J Chem Inf Model. 2014 Oct 27;54(10):2915-44. doi: 10.1021/ci500305c. Epub 2014 Oct 9.
4
Structure-based discovery of antagonists of nuclear receptor LRH-1.基于结构的核受体 LRH-1 拮抗剂的发现。
J Biol Chem. 2013 Jul 5;288(27):19830-44. doi: 10.1074/jbc.M112.411686. Epub 2013 May 10.
5
Nuclear receptors and their selective pharmacologic modulators.核受体及其选择性药理调节剂。
Pharmacol Rev. 2013 Mar 1;65(2):710-78. doi: 10.1124/pr.112.006833. Print 2013 Apr.
6
Orphan nuclear receptor modulators.孤儿核受体调节剂
Curr Top Med Chem. 2003;3(14):1637-47. doi: 10.2174/1568026033451709.
7
Rational discovery of novel type-III FTF antagonists to competitively suppress TIF-2 coactivation in liver cancer.合理发现新型III型FTF拮抗剂以竞争性抑制肝癌中的TIF-2共激活。
J Recept Signal Transduct Res. 2019 Aug;39(4):304-311. doi: 10.1080/10799893.2019.1690513. Epub 2019 Nov 22.
8
Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.法尼醇 X 受体配体的药物化学:从激动剂和拮抗剂到调节剂。
Future Med Chem. 2012 May;4(8):1015-36. doi: 10.4155/fmc.12.47.
9
Hybrid Reporter Gene Assays: Versatile In Vitro Tools to Characterize Nuclear Receptor Modulators.杂交报告基因检测:用于表征核受体调节剂的多功能体外工具。
Methods Mol Biol. 2019;1966:175-192. doi: 10.1007/978-1-4939-9195-2_14.
10
Current in vitro high throughput screening approaches to assess nuclear receptor activation.当前评估核受体激活的体外高通量筛选方法。
Curr Drug Metab. 2010 Nov;11(9):806-14. doi: 10.2174/138920010794328896.

引用本文的文献

1
A Small-Molecule Compound Targeting Canine Mammary Cancer Regulates CXCL10 and MECOM Transcripts via Histone Modifications in CMT-N7.一种靶向犬乳腺癌的小分子化合物通过CMT-N7中的组蛋白修饰调节CXCL10和MECOM转录本。
Animals (Basel). 2025 Aug 4;15(15):2274. doi: 10.3390/ani15152274.
2
A novel heuristic of rigid docking scores positively correlates with full-length nuclear receptor LRH-1 regulation.一种新型刚性对接评分启发式方法与全长核受体LRH-1调控呈正相关。
Comput Struct Biotechnol J. 2024 Jul 30;23:3065-3080. doi: 10.1016/j.csbj.2024.07.021. eCollection 2024 Dec.
3
New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1.

本文引用的文献

1
Computer-Aided Ligand Discovery for Estrogen Receptor Alpha.计算机辅助配体发现雌激素受体 α。
Int J Mol Sci. 2020 Jun 12;21(12):4193. doi: 10.3390/ijms21124193.
2
Nuclear receptor crosstalk - defining the mechanisms for therapeutic innovation.核受体相互作用——确定治疗创新的机制
Nat Rev Endocrinol. 2020 Jul;16(7):363-377. doi: 10.1038/s41574-020-0349-5. Epub 2020 Apr 17.
3
Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90).鉴定热休克蛋白 90(Hsp90)中段结构域的同工型选择性配体。
高通量筛选发现全长核受体 LRH-1 的新型配体。
ACS Chem Biol. 2023 May 19;18(5):1101-1114. doi: 10.1021/acschembio.2c00805. Epub 2023 Apr 19.
4
Natural compounds targeting nuclear receptors for effective cancer therapy.靶向核受体的天然化合物在癌症治疗中的应用。
Cancer Metastasis Rev. 2023 Sep;42(3):765-822. doi: 10.1007/s10555-022-10068-w. Epub 2022 Dec 8.
5
Increased Molecular Flexibility Widens the Gap between and values in Screening for Retinoid X Receptor Modulators.分子柔韧性增加扩大了类视黄醇X受体调节剂筛选中 与 值之间的差距。 (原文中两个“ ”处信息缺失)
ACS Med Chem Lett. 2022 Jan 21;13(2):211-217. doi: 10.1021/acsmedchemlett.1c00575. eCollection 2022 Feb 10.
6
Structural overview and perspectives of the nuclear receptors, a major family as the direct targets for small-molecule drugs.核受体的结构概述和展望,作为小分子药物的直接靶点,这一家族非常重要。
Acta Biochim Biophys Sin (Shanghai). 2022 Jan 25;54(1):12-24. doi: 10.3724/abbs.2021001.
7
The Role of Androgens and Androgen Receptor in Human Bladder Cancer.雄激素和雄激素受体在膀胱癌中的作用。
Biomolecules. 2021 Apr 18;11(4):594. doi: 10.3390/biom11040594.
Int J Mol Sci. 2019 Oct 26;20(21):5333. doi: 10.3390/ijms20215333.
4
Development of a Cell-Based Ligand-Screening System for Identifying Hsp90 Inhibitors.开发基于细胞的配体筛选系统,用于鉴定 HSP90 抑制剂。
Biochemistry. 2020 Jan 21;59(2):179-182. doi: 10.1021/acs.biochem.9b00781. Epub 2019 Oct 11.
5
Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library.在 Tox21 化学文库中发现有限的化学结构多样性可调节甲状腺激素受体。
Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30.
6
Discovery of retinoic acid receptor agonists as proliferators of cardiac progenitor cells through a phenotypic screening approach.通过表型筛选方法发现维甲酸受体激动剂作为心脏祖细胞的增殖剂。
Stem Cells Transl Med. 2020 Jan;9(1):47-60. doi: 10.1002/sctm.19-0069. Epub 2019 Sep 11.
7
Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.通过开发基于荧光偏振的竞争测定法,鉴定肝 X 受体 β 调节剂构建模块。
Eur J Med Chem. 2019 Sep 15;178:458-467. doi: 10.1016/j.ejmech.2019.06.011. Epub 2019 Jun 10.
8
The next level in chemical space navigation: going far beyond enumerable compound libraries.化学空间导航的下一个层次:超越可枚举的化合物库。
Drug Discov Today. 2019 May;24(5):1148-1156. doi: 10.1016/j.drudis.2019.02.013. Epub 2019 Mar 7.
9
Development of a Ligand Screening Tool Using Full-Length Human Peroxisome Proliferator-Activated Receptor-Expressing Cell Lines to Ameliorate Metabolic Syndrome.利用表达全长人过氧化物酶体增殖物激活受体的细胞系开发一种配体筛选工具以改善代谢综合征。
Chem Pharm Bull (Tokyo). 2019;67(3):199-202. doi: 10.1248/cpb.c18-00627.
10
Identification of FDA-approved drugs targeting the Farnesoid X Receptor.鉴定法尼醇 X 受体的 FDA 批准药物。
Sci Rep. 2019 Feb 18;9(1):2193. doi: 10.1038/s41598-019-38668-7.